구조모아 (StructureMoa)항암 chemical structure spider web
방문Brentuximab(Seagen / Takeda)은 Diffuse Large B Cell Lymphoma 표적 항체로, Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 64% (ClinicalTrials.gov NCT01909934). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma
Discontinued
2026-07-13
Data Confidence · Low
Development Signal · Emerging
ADCs) increased the antitumor effect of mAbs
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
cytokine release syndrome in a peripheral blood mononuclear cell derived humanized mouse model
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
구조화 데이터
xenograft model
mouse
pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Brentuximab(Seagen / Takeda)은 Diffuse Large B Cell Lymphoma 표적 항체로, Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 64% (ClinicalTrials.gov NCT01909934). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma
Discontinued
2026-07-13
Data Confidence · Low
Development Signal · Emerging
ADCs) increased the antitumor effect of mAbs
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
cytokine release syndrome in a peripheral blood mononuclear cell derived humanized mouse model
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
구조화 데이터
xenograft model
mouse
pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.